When added to standard of care, tezepelumab demonstrated a statistically significant and clinically meaningful reduction in the annualized asthma exacerbation rate in patients with severe, uncontrolled asthma, compared to placebo.
The results were presented at the American Academy of Asthma Allergy and Immunology annual meeting. NAVIGATOR is a pivotal Phase 3 trial that will form the basis of regulatory filing.
Tezepelumab, a potential first-in-class medicine, when added to standard of care achieved a 56% reduction (p
Inimmune signs research collaboration with Boston Children's Hospital
ResVita Bio receives USD250,000 phase one Small Business Innovation Research grant from NIAID
Phase II Data of Oral Dexpramipexole Published in Eosinophilic Asthma
AllerVie Health Rebrands Southern Allergy & Asthma
Applied BioCode Inks Distribution Agreement with Medline Industries
Vedanta Biosciences Receives Fast Track Designation for VE303
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop
French Ophthalmology Specialist Horus Pharma Group Launches a Nordic Subsidiary